Alkermes plc. recently announced that the Food & Drug Administration (FDA) approved Aristada Initio (aripiprazole lauroxil) for schizophrenia in adults. The approval makes the drug the first and only long-acting atypical antipsychotic that can be initiated on day one for the treatment of schizophrenia.
Compared to Alkermes’ injectable atypical antipsychotic medication, Aristada, Aristada Initio utilizes a smaller particle size, provides faster dissolution, and allows clinical professionals and caregivers to fully dose individuals for up to two months. It is anticipated that the drug will become available this month.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
This was reported by Zacks on July 3, 2018.
Contact Information: Alkermes plc, 852 Winter Street, Waltham, Massachusetts 02451; (781) 609-6000; Website: www.alkermes.com